Valuation: TapImmune Inc

Market Cap 20.51M 17.76M 16.56M 15.23M 28.75M 1.95B 29.07M 195M 76.37M 976M 77.02M 75.33M 3.23B P/E 2026 *
-1.28x
P/E 2027 * -1.21x
Enterprise Value 20.51M 17.76M 16.56M 15.23M 28.75M 1.95B 29.07M 195M 76.37M 976M 77.02M 75.33M 3.23B EV / Sales 2026 *
7.25x
EV / Sales 2027 * 1.02x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 46 01/05/2023
Chief Operating Officer 36 01/12/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 17/10/2018
Chairman 65 24/05/2022
Director/Board Member 62 06/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-12.24% - - 20.51M
+0.90%-2.33%+0.68%+14.52% 48B
+1.81%+8.31%+410.42%+561.10% 41.13B
+3.29%-4.64%+28.35%+7.65% 37.56B
+2.21%+0.60%+7.15%+75.55% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
+0.38%-2.83% - - 16.12B
+1.02%-0.39%+33.54%+123.76% 16.05B
+1.25%+1.52%+4.62%+18.66% 13.76B
+4.41%-8.08%-1.33%-34.90% 12.1B
Average +2.13%-2.15%+62.29%+101.39% 27.83B
Weighted average by Cap. +1.83%-1.29%+82.20%+127.72%

Financials

2026 *2027 *
Net sales 2.83M 2.45M 2.29M 2.1M 3.97M 269M 4.01M 26.85M 10.54M 135M 10.63M 10.4M 446M 20.09M 17.4M 16.22M 14.91M 28.16M 1.91B 28.47M 191M 74.79M 956M 75.44M 73.77M 3.16B
Net income -19.36M -16.77M -15.63M -14.38M -27.14M -1.84B -27.45M -184M -72.1M -921M -72.72M -71.12M -3.05B -19.89M -17.23M -16.06M -14.77M -27.88M -1.89B -28.2M -189M -74.07M -946M -74.71M -73.06M -3.13B
Net Debt - -
Logo TapImmune Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-